ArticleNeuro-oncology2018
Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Significance of Early Proton Beam Therapy Initiation in Achieving Complete Response in Pediatric Medulloblastoma: A Retrospective Study.Cancer medicine · 2026Article
- Early Initiation of Adjuvant Therapy Following Pediatric Endoscopic Endonasal Surgery for Tumors.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Treatment Outcomes and Prognostic Factors for Patients With Medulloblastoma Having Defined Molecular Subtypes.Advances in radiation oncology · 2025Article
- Medulloblastoma in Adolescents and Young Adults (AYA): Bridging Pediatric Paradigms and Adult Oncology Practice.Journal of clinical medicine · 2025Review
- The Role of CyberKnife Stereotactic Radiosurgery in Recurrent Cranial Medulloblastomas across Pediatric and Adult Populations.Journal of clinical medicine · 2024Article
- Long-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma.Cancer research and treatment · 2024Article
- Feasibility and Safety of Implementing Volumetric Arc Therapy (VMAT) for Pediatric Craniospinal Irradiation in a Low-Middle-Income Region: The Nigerian Experience.Advances in radiation oncology · 2024Article
- Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network.Journal of neuro-oncology · 2023Observational
- Postoperative radiotherapy timing, molecular subgroups and treatment outcomes of Thai pediatric patients with medulloblastoma.PloS one · 2023Article
- New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma.Cancers · 2022Review
- Postoperative hydrocephalus management may cause delays in adjuvant treatment following paediatric posterior fossa tumour resection: a multicentre retrospective observational study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Observational
- Referral Patterns and Treatment Delays in Medulloblastoma: A Large Academic Proton Center Experience.International journal of particle therapy · 2021Article
- Real-world data for pediatric medulloblastoma: can we improve outcomes?European journal of pediatrics · 2021Article
- Delayed postoperative radiotherapy might improve the long-term prognosis of locally advanced esophageal squamous cell carcinoma.Translational oncology · 2021Article
- Medulloblastoma: an Old Diagnosis with New Promises.Current oncology reports · 2020Review
- Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.Cancer metastasis reviews · 2020Review
- Medulloblastoma: optimizing care with a multidisciplinary approach.Journal of multidisciplinary healthcare · 2019Review
- Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial.Advances in radiation oncologyArticle
- Development of an integrated risk stratification model for metastatic medulloblastoma (M2/3) using clinical, radiologic, and molecular variables.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation therapy (RT) remains a critical component of multimodality treatment for medulloblastoma. Traditionally, clinicians strive to start RT within 4-5 weeks of surgery, but the optimal timing after surgery remains unclear. Methods: Using the National Cancer Database, we identified pediatric and adolescent patients with medulloblastoma treated with curative-intent surgery, RT, and chemotherapy. Factors associated with early or delayed RT were identified using Pearson chi-squared tests. Overall survival (OS) differences based on RT timing were compared using the Kaplan-Meier estimator with log-rank tests. Patient, tumor, and treatment characteristics associated with OS were analyzed with univariate and multivariate Cox proportional hazards models. Results: Among the 1338 patients analyzed, early RT (defined as initiation ≤3 wk after surgery) was associated with younger age, M1-3 disease, and subtotal resection. Patients who initiated RT early had decreased 5-year OS compared with patients who initiated RT 3.1-4, 4.1-5, or >5 weeks after surgery (72.5% vs. 80.5%, 79.4%, and 77.8%, respectively; P = 0.019), but there was no significant difference in OS among the latter 3 groups (P = 0.788). On multivariate analysis, early RT versus the 3.1- to 4-week interval was significantly associated with poorer OS (adjusted hazard ratio, 1.72; 95% CI: 1.19-2.48; P = 0.004), while time to RT of >5 weeks but within 90 days of surgery did not adversely impact OS (P = 0.563). Conclusions: In this large national database analysis, delaying RT within 90 days of surgery was not associated with inferior outcomes. Although clinical judgment remains paramount, postoperative RT timing should allow for healing and the development of an optimal treatment plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.